Jamie Dwyer (University of Utah)

Executive Associate Vice President of Research; Chief Innovation Officer; Director, Utah Data Coordinating Center

CKD progression, AKI, endpoints in CKD clinical trials, CKD progression in CVOT

Dwyer JP, Maklad N, Vedin O, Monyak J, Myte R, Chertow GM, Heerspink HJL, Little DJ. Efficacy and Safety of Baxdrostat in Participants with CKD and Uncontrolled Hypertension: A Randomized, Double-Blind, Placebo-Controlled Trial. J Am Soc Nephrol. 2025. PMID 40913594.

Flack JM, Azizi M, Brown JM, Dwyer JP, Fronczek J, Jones ESW, Olsson DS, Perl S, Shibata H, Wang JG, Wilderäng U, Wittes J, Williams B, for the BaxHTN Investigators. Baxdrostat Efficacy and Safety in Uncontrolled and Resistant Hypertension. N Engl J Med. 2025. PMID 40888730.

Azizi M, Brown JM, Dwyer JP, Flack JM, Jones ESW, Kurlyandskaya R, Lis H, Birve F, Linhn A, Perl S, Schlaich MP, Shibata H, Wang JG, Williams B, for the Bax24 Investigators. Effect of Baxdrostat on Ambulatory Blood Pressure in Patients with Resistant Hypertension (Bax24): a Phase 3 Randomised, Double-blind, Placebo-controlled trial. Lancet. 2026;407(10532):988–999. PMID 41794437.

Wagenlehner FME, Cloutier DJ, Komirenko AS, Cebrik DS, Krause KM, Keepers TR, Connolly LE, Miller LG, Friedland I, Dwyer JP; EPIC Study Group. Once-Daily Plazomicin for Complicated Urinary Tract Infections. N Engl J Med. 2019;380(8):729–740. PMID 30786187.